List of bibliographic references
Number of relevant bibliographic references: 42.
[0-20] [
0 - 20][
0 - 42][
20-40]
Ident. | Authors (with country if any) | Title |
---|
000170 (2016) |
Annalisa Pinna [Italie] ; Wai Kin D. Ko [Royaume-Uni] ; Giulia Costa [Italie] ; Elisabetta Tronci [Italie] ; Camino Fidalgo [Italie] ; Nicola Simola [Italie] ; Qin Li [Royaume-Uni] ; Mojgan Aghazadeh Tabrizi [Italie] ; Erwan Bezard [Royaume-Uni] ; Manolo Carta [Italie] ; Micaela Morelli [Italie] | Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. |
000258 (2015) |
Rodolphe Hajj [France] ; Aude Milet [France] ; Damien Toulorge [France] ; Nathalie Cholet [France] ; Julien Laffaire [France] ; Julie Foucquier [France] ; Sandra Robelet [France] ; Richard Mitry [France] ; Mickael Guedj [France] ; Serguei Nabirotchkin [France] ; Ilya Chumakov [France] ; Daniel Cohen [France] | Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease. |
000272 (2015) |
Romain Lefaucheur [France] ; Floriane Le Goff [France] ; Gaëlle Gaillon [France] ; Aude Triquenot-Bagan [France] ; David Maltête [France] | Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction? |
000281 (2015) |
Clive Ballard [Royaume-Uni] ; Stuart Isaacson [États-Unis] ; Roger Mills [États-Unis] ; Hilde Williams [États-Unis] ; Anne Corbett [Royaume-Uni] ; Bruce Coate [États-Unis] ; Rajesh Pahwa [États-Unis] ; Olivier Rascol [France] ; David J. Burn [Royaume-Uni] | Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. |
000549 (2014) |
María Ver Nica Rey [Argentine] ; Santiago Perez-Lloret ; Anne Pavy-Le Traon ; Wassilios G. Meissner ; Francois Tison ; Olivier Rascol | A cross-sectional study on drug use in multiple system atrophy. |
000552 (2014) |
Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. Facheris | Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. |
000669 (2013) |
Fanny Duval [France] ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François Tison | Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome. |
000951 (2011) |
O. Rascol [France] | Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. |
000988 (2010) |
Santiago Perez-Lloret [France] ; Olivier Rascol | Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. |
000C41 (2008) |
P. Damier [France] ; F. Viallet ; M. Ziegler ; I. Bourdeix ; K. Rerat | Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. |
000D73 (2007) |
Matthias Fargel [Allemagne] ; Bernd Grobe ; Eberhard Oesterle ; Claudia Hastedt ; Markus Rupp | Treatment of Parkinson's disease: a survey of patients and neurologists. |
000D92 (2006) |
Nathalie Turle-Lorenzo [France] ; Béatrice Maurin ; Carole Puma ; Claire Chezaubernard ; Philippe Morain ; Christelle Baunez ; André Nieoullon ; Marianne Amalric | The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. |
000D95 (2006) |
Olivier Rascol [France] ; David J. Brooks ; Amos D. Korczyn ; Peter P. De Deyn ; Carl E. Clarke ; Anthony E. Lang ; Mona Abdalla | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. |
000E37 (2006) |
Joumana Hudry [France] ; Juha O. Rinne ; Tapani Ker Nen ; Laurent Eckert ; John M. Cochran | Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. |
000F17 (2005) |
| Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. |
000F19 (????) |
O. Rascol [France] ; D J Brooks ; E. Melamed ; W. Oertel ; W. Poewe ; F. Stocchi ; E. Tolosa | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. |
000F86 (2004) |
| Extrapyramidal reactions to SSRI antidepressant + neuroleptic combinations. |
001019 (2003) |
Patrice Boyer [France] | Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance? |
001071 (2003) |
Marc Ziegler [France] ; Alexandre Castro-Caldas ; Susanna Del Signore ; Olivier Rascol | Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. |
001076 (2003) |
G. Fénelon [France] ; S. Giménez-Roldán ; J L Montastruc ; F. Bermejo ; F. Durif ; I. Bourdeix ; J-J Péré ; L. Galiano ; J. Schadrack | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. |
001105 (2003) |
N V Fedorova | [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study]. |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/MedMesh.i -k "Drug Therapy, Combination"
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/MedMesh.i \
-Sk "Drug Therapy, Combination" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= indexItem
|index= MedMesh.i
|clé= Drug Therapy, Combination
}}
| This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024 | |